Orion Corporation Completes Share Buyback Program

On September 4, 2026, Orion Corporation announced the acquisition of its own shares as part of a planned buyback programme. The shares were purchased between September 1 and September 23, 2026, in compliance with European regulations.

According to the company, these buybacks are part of a share repurchase programme that Orion Corporation initiated on August 27, 2026. The programme, which runs until December 31, 2026, is executed in accordance with the Market Abuse Regulation (MAR) and the Commission Delegated Regulation (EU) 2016/1052.

As of the latest acquisitions, Orion Corporation now holds 370,888 treasury shares, all of which are Class B shares. These shares were acquired at an average price, rounded to four decimal places, as per the company's records.

Orion Pharma, a globally operating Nordic pharmaceutical company, focuses on developing, manufacturing, and marketing human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients. With an extensive portfolio of proprietary and generic medicines and consumer health products, Orion's core therapy areas include oncology and pain management. The company's proprietary products are used to treat a range of conditions, including cancer, respiratory diseases, and neurological diseases.

In 2025, Orion Corporation reported net sales of €1.89 billion, employing approximately 4,000 professionals worldwide in its mission to build well-being.

These buybacks are a significant move in the company’s strategy to optimize its capital structure, reflecting the ongoing commitment to shareholder value.